We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan · Delayed Price · Currency is TWD 31.90
+0.25 (0.79%)
Aug 1, 2025, 1:20 PM CST
We Can Medicines Revenue
We Can Medicines had revenue of 797.87M TWD in the quarter ending March 31, 2025, a decrease of -2.47%. This brings the company's revenue in the last twelve months to 3.25B, up 2.51% year-over-year. In the year 2024, We Can Medicines had annual revenue of 3.27B with 4.69% growth.
Revenue (ttm)
3.25B
Revenue Growth
+2.51%
P/S Ratio
0.44
Revenue / Employee
3.23M
Employees
1,005
Market Cap
1.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.27B | 146.31M | 4.69% |
| Dec 31, 2023 | 3.12B | -179.84M | -5.45% |
| Dec 31, 2022 | 3.30B | 508.66M | 18.21% |
| Dec 31, 2021 | 2.79B | 127.32M | 4.77% |
| Dec 31, 2020 | 2.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-President Enterprises | 668.15B |
| President Chain Store | 346.04B |
| Great Wall Enterprise | 102.97B |
| Lian Hwa Foods | 12.42B |
| Charoen Pokphand Enterprise (Taiwan) | 27.74B |
| Standard Foods | 29.06B |
| TTET Union | 21.60B |
| Hey Song | 9.84B |